AXSM
BEARISH
$185.96
Live
Axsome Therapeutics, Inc. · NASDAQ
Target $210.19
(+13.0%)
$86.99
52W Range
$191.5
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$9.37B
P/E
N/A
ROE
-275.5%
Profit margin
-40.9%
Debt/Equity
2.96
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
68%
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, indicating significant operational and profitability concerns. Despite strong revenue growth of 63.2% and a bullish analyst recommendation, the company is deeply unprofitable with a -40.89% profit margin, negative ROE of -275.50%, and a high debt/equity ratio of 2.96. Valuation metrics are stretched, with a forward P/E of 423x and a price-to-book of 126.85, while insider selling of $85.54M in the last six months signals strong bearish sentiment from management. Although the stock has delivered impressive price performance over the past year (+79%), these gains appear disconnected from fundamentals, increasing vulnerability to downside correction.
Key Strengths
Exceptional year-over-year revenue growth of 63.20%, significantly above sector average of 39.78%
High gross margin of 91.86%, indicating strong pricing power and low cost of goods sold
Analyst consensus is strong_buy with a target price of $210.19, implying 13% upside
Recent earnings surprises have trended positive, with 2 out of last 4 quarters beating estimates
Strong historical price performance: +162.6% over 3 years and +79.0% over 1 year
Key Risks
Piotroski F-Score of 3/9 indicates weak financial health and poor profitability trends
Extremely high forward P/E of 423x with no Graham Number, suggesting severe overvaluation relative to earnings
Negative ROE of -275.50% and negative operating margins signal deep profitability issues
Debt/Equity ratio of 2.96 is above sector average (2.84), increasing financial risk
Massive insider selling of $85.54M in 6 months, with CEO and directors actively reducing holdings
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
28
Weak
15
65
40
20
0
AI Verdict
High-risk speculative position with unsustainable valuation and weak fundamentals despite growth and analyst optimism.
Key drivers: Low Piotroski F-Score (3/9), Negative profitability across all margins, Extreme valuation multiples, Heavy insider selling, Analyst optimism and revenue growth
Confidence
70%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- None
Watchpoints
- Forward P/E of 423.03 is extremely elevated
- Price/Book of 126.85 indicates massive premium to book value
- No Graham Number due to unprofitability
- No meaningful free cash flow or EBITDA for valuation
Future
65/100
Ref Growth rates
Positives
- Revenue growth of 63.20% YoY is exceptional
- Earnings growth of 29.9% YoY shows some improvement
- Analyst target suggests 13% upside
Watchpoints
- Earnings growth based on negative EPS, limiting sustainability
- No PEG ratio due to unprofitability
Past
40/100
Ref Historical trends
Positives
- Stock up 162.6% over 3 years
- Recent quarters show improved earnings surprise trend
Watchpoints
- History of large earnings misses, including -74.8% surprise in Q1 2024
- Consistently negative EPS across all 25 quarters
- Profitability has not improved meaningfully over time
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.57 and quick ratio of 1.45 indicate short-term liquidity
Watchpoints
- Piotroski F-Score of 3/9 indicates weak financial health
- Altman Z-Score unavailable, but negative ROE and high leverage suggest distress risk
- Debt/Equity of 2.96 is high
- ROE of -275.50% and ROA of -19.79% reflect severe unprofitability
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield
- Dividend strength score of 0/100
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$185.96
Analyst Target
$210.19
Upside/Downside
+13.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AXSM and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
Primary
|
+146.1% | +162.6% | +79.0% | +84.4% | +21.0% | +4.9% |
|
MASI
Masimo Corporation
Peer
|
-25.5% | -6.9% | +16.2% | +20.6% | +1.7% | -0.0% |
|
TECH
Bio-Techne Corporation
Peer
|
-41.6% | -26.4% | +28.2% | -2.9% | +17.7% | +5.3% |
|
ICLR
ICON Public Limited Company
Peer
|
-43.0% | -45.5% | -19.8% | -38.0% | +19.4% | +9.3% |
|
BIO-B
Bio-Rad Laboratories, Inc.
Peer
|
-47.0% | -22.7% | -10.4% | +26.6% | +0.7% | +0.7% |
AXS
Axsome Therapeutics, Inc.
Primary
5Y
+146.1%
3Y
+162.6%
1Y
+79.0%
6M
+84.4%
1M
+21.0%
1W
+4.9%
MAS
Masimo Corporation
Peer
5Y
-25.5%
3Y
-6.9%
1Y
+16.2%
6M
+20.6%
1M
+1.7%
1W
-0.0%
TEC
Bio-Techne Corporation
Peer
5Y
-41.6%
3Y
-26.4%
1Y
+28.2%
6M
-2.9%
1M
+17.7%
1W
+5.3%
ICL
ICON Public Limited Company
Peer
5Y
-43.0%
3Y
-45.5%
1Y
-19.8%
6M
-38.0%
1M
+19.4%
1W
+9.3%
BIO
Bio-Rad Laboratories, Inc.
Peer
5Y
-47.0%
3Y
-22.7%
1Y
-10.4%
6M
+26.6%
1M
+0.7%
1W
+0.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
423.03
PEG Ratio
N/A
P/B Ratio
126.85
P/S Ratio
16.7
EV/Revenue
16.51
EV/EBITDA
-49.31
Market Cap
$9.37B
Profitability
Profit margins and return metrics
Profit Margin
-40.89%
Operating Margin
-19.25%
Gross Margin
91.86%
ROE
-275.5%
ROA
-19.79%
Growth
Revenue and earnings growth rates
Revenue Growth
+63.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
2.96
High debt
Current Ratio
1.57
Good
Quick Ratio
1.45
Good
Cash/Share
$6.45
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-17
$N/A
2025-11-03
$-0.94
-4.2% surprise
2025-08-04
$-0.97
+10.8% surprise
2025-05-05
$-1.22
+9.5% surprise
Healthcare Sector Comparison
Comparing AXSM against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-275.5%
This Stock
vs
-88.14%
Sector Avg
+212.6%
(Excellent)
Profit Margin
-40.89%
This Stock
vs
-16.28%
Sector Avg
+151.2%
(Superior)
Debt to Equity
2.96
This Stock
vs
2.66
Sector Avg
+11.4%
(Higher)
Revenue Growth
63.2%
This Stock
vs
124.04%
Sector Avg
-49.0%
(Slower)
Current Ratio
1.57
This Stock
vs
4.47
Sector Avg
-64.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
|
BEARISH | $9.37B | - | -275.5% | -40.9% | $185.96 | |
|
MASI
Masimo Corporation
|
BEARISH | $9.35B | 46.6 | 23.4% | -9.9% | $178.47 | Compare |
|
TECH
Bio-Techne Corporation
|
NEUTRAL | $9.48B | 114.3 | 4.0% | 6.7% | $60.58 | Compare |
|
ICLR
ICON Public Limited Company
|
NEUTRAL | $9.06B | 15.7 | 6.3% | 7.4% | $116.5 | Compare |
|
BIO-B
Bio-Rad Laboratories, Inc.
|
BEARISH | $9.79B | - | -9.5% | -26.4% | $312.75 | Compare |
AXSM
Axsome Therapeutics, Inc.
BEARISH
Mkt Cap
$9.4B
P/E
-
ROE
-275.5%
Price
$185.96
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-07 | TABUTEAU HERRIOT | Chief Executive Officer | Option Exercise | 139,414 | $1,118,100 |
| 2026-01-07 | TABUTEAU HERRIOT | Chief Executive Officer | Sale | 139,414 | $23,881,618 |
| 2025-12-31 | SAAD MARK E | Director | Option Exercise | 37,577 | $205,135 |
| 2025-12-31 | SAAD MARK E | Director | Sale | 37,577 | $6,206,969 |
| 2025-12-04 | TABUTEAU HERRIOT | Chief Executive Officer | Option Exercise | 79,973 | $641,383 |
| 2025-12-04 | TABUTEAU HERRIOT | Chief Executive Officer | Sale | 79,973 | $11,648,582 |
| 2025-11-05 | TABUTEAU HERRIOT | Chief Executive Officer | Option Exercise | 163,939 | $1,314,791 |
| 2025-11-05 | TABUTEAU HERRIOT | Chief Executive Officer | Sale | 163,939 | $21,815,669 |
| 2025-10-08 | TABUTEAU HERRIOT | Chief Executive Officer | Option Exercise | 45,384 | $363,980 |
| 2025-10-08 | TABUTEAU HERRIOT | Chief Executive Officer | Sale | 45,384 | $5,418,060 |
| 2025-09-22 | JACOBSON MARK L | Chief Operating Officer | Option Exercise | 10,000 | $28,500 |
| 2025-09-22 | JACOBSON MARK L | Chief Operating Officer | Sale | 10,000 | $1,159,600 |
| 2025-09-16 | TABUTEAU HERRIOT | Chief Executive Officer | Option Exercise | 62,880 | $504,298 |
| 2025-09-16 | JACOBSON MARK L | Chief Operating Officer | Option Exercise | 40,000 | $196,500 |
| 2025-09-16 | TABUTEAU HERRIOT | Chief Executive Officer | Sale | 62,880 | $7,361,891 |
TABUTEAU HERRIOT
Chief Executive Officer
2026-01-07
139,414 shares
·
$1,118,100
TABUTEAU HERRIOT
Chief Executive Officer
2026-01-07
139,414 shares
·
$23,881,618
SAAD MARK E
Director
2025-12-31
37,577 shares
·
$205,135
SAAD MARK E
Director
2025-12-31
37,577 shares
·
$6,206,969
TABUTEAU HERRIOT
Chief Executive Officer
2025-12-04
79,973 shares
·
$641,383
TABUTEAU HERRIOT
Chief Executive Officer
2025-12-04
79,973 shares
·
$11,648,582
TABUTEAU HERRIOT
Chief Executive Officer
2025-11-05
163,939 shares
·
$1,314,791
TABUTEAU HERRIOT
Chief Executive Officer
2025-11-05
163,939 shares
·
$21,815,669
TABUTEAU HERRIOT
Chief Executive Officer
2025-10-08
45,384 shares
·
$363,980
TABUTEAU HERRIOT
Chief Executive Officer
2025-10-08
45,384 shares
·
$5,418,060
JACOBSON MARK L
Chief Operating Officer
2025-09-22
10,000 shares
·
$28,500
JACOBSON MARK L
Chief Operating Officer
2025-09-22
10,000 shares
·
$1,159,600
TABUTEAU HERRIOT
Chief Executive Officer
2025-09-16
62,880 shares
·
$504,298
JACOBSON MARK L
Chief Operating Officer
2025-09-16
40,000 shares
·
$196,500
TABUTEAU HERRIOT
Chief Executive Officer
2025-09-16
62,880 shares
·
$7,361,891
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
20 analysts
RBC Capital
2026-01-21
Outperform
Outperform
HC Wainwright & Co.
2026-01-20
Buy
Buy
Piper Sandler
2026-01-16
Overweight
Overweight
Wells Fargo
2026-01-13
Overweight
Overweight
Morgan Stanley
2026-01-08
Overweight
Equal-Weight
UBS
2026-01-06
Buy
Buy
HC Wainwright & Co.
2026-01-05
Buy
Buy
Needham
2025-12-31
Buy
Buy
Mizuho
2025-11-06
Outperform
Outperform
Morgan Stanley
2025-11-04
Overweight
Overweight
Past News Coverage
Recent headlines mentioning AXSM from our newsroom.
Newest → oldest
No matching news yet.